Proper Dosage of Ketamine in Intravenous Regional Anesthesia

Pain. Clinical Trial

Official title:

Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00221871
• Other study ID #: UHN02-0233-A
• Status: Recruiting
• Phase: N/A
• First received: September 20, 2005
• Last updated: October 10, 2006
• Start date: January 2004
• Est. completion date: January 2005

Study information

• Verified date: September 2005
• Source: University Health Network, Toronto
• Contact: Colin McCartney, MD
• Phone: (416)603-5118
• Email: colin.mccartney[@]uhn.on.ca
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 0
• Est. completion date: January 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age: 18-70

2. Weight: 50-100 kg

3. ASA: I, II, III

4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion Criteria:

1. Contraindication to IVRA such as sickle cell disease.

2. Any known hypersensitivity reaction to Ketamine.

3. History of chronic pain or regular medication with analgesics.

4. History of opioid dependence.

5. Drug of alcohol abuse.

6. Psychiatric disorder.

7. Allergy to acetaminophen or codeine

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pain.

Intervention

Drug:
• Different dosages of Ketamine

Locations

Country	Name	City	State
Canada	University Health Network	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada,